Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for new-onset or relapsing giant cell arteritis
MOH_2021-07-15_010147Phase 2Completed
- Sponsor
- Janssen-Cilag
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started Jun 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on MOH_2021-07-15_010147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-15_010147.